Results 171 to 180 of about 9,263,992 (362)
PREVALANCE AND ASSOCIATED RISK FACTORS FOR SYPHILIS IN WOMENS WITH RECURRENTS MISCARRIAGE
, 1969 Arshad Hussain Laghari +5 more
openalex +1 more source
Coronary heart disease: Risk factors as guides to preventive action [PDF]
, 1972 Jeremiah Stamler, Frederick H. Epstein
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular Oncology, EarlyView.Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source
Coronary Heart Disease Risk Factors: A Comparison of Two Puerto Rican Populations
, 1966 Herbert Benson +6 more
openalex +2 more sources
Vigorous exercise in leisure time, coronary risk-factors, and resting electrocardiogram in middle-aged male civil servants. [PDF]
, 1976 L. H. Epstein +3 more
openalex +1 more source
Molecular Oncology, EarlyView.A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
Molecular Oncology, EarlyView.This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian +10 more
wiley +1 more source
Risk Factors and Prevalence of Coronary Heart Disease in Puerto Rico [PDF]
, 1970 Mario R. García-Palmieri +10 more
openalex +1 more source
Molecular Oncology, EarlyView.This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source